[Using thromboelastography to measure coagulation following massive blood loss]

Area of Science:

• Coagulation Science
• Critical Care Medicine
• Point-of-Care Testing

Background:

• Massive blood loss presents significant diagnostic and therapeutic challenges.
• Accurate and rapid assessment of coagulation status is crucial for effective management.
• Traditional coagulation tests may not fully capture the dynamic nature of hemostasis in critical illness.

Purpose of the Study:

• To evaluate the diagnostic utility of thromboelastography (TEG) in patients with massive blood loss.
• To assess the impact of TEG-guided blood product management on patient outcomes and resource utilization.
• To highlight the role of TEG as a point-of-care diagnostic tool in critical care.

Main Methods:

• Whole-blood kaolin-activated thromboelastography was performed.
• TEG parameters including clot formation time, maximal clot strength, and fibrinolysis were analyzed.
• Clinical data on blood product transfusion and patient outcomes were collected and compared.

Main Results:

• Thromboelastography provides comprehensive information on clot kinetics, strength, and stability.
• TEG-guided therapy led to reduced use of blood products in cardiac surgery, trauma, and liver transplant patients.
• The technique is adaptable for both rapid point-of-care testing and central laboratory analysis.

Conclusions:

• Thromboelastography is a valuable tool for diagnosing coagulation disorders in patients with massive blood loss.
• Implementing TEG can optimize blood product transfusion strategies, leading to cost savings and improved patient care.
• Further research is ongoing to explore TEG's application in diverse patient populations experiencing critical bleeding.